TY - JOUR
T1 - Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features
AU - Maruyama, R.
AU - Toyooka, S.
AU - Toyooka, K. O.
AU - Harada, K.
AU - Virmani, A. K.
AU - Zöchbauer-Müller, S.
AU - Farinas, A. J.
AU - Minna, John D
AU - Gazdar, Adi F
AU - Sagalowsky, A.
AU - Czerniak, B.
AU - Sagalowsky, Arthur I
PY - 2001/12/15
Y1 - 2001/12/15
N2 - We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RARβ, 11% for GSTP1, 7% for p16INK4A, 4% for DAPK, and 2% for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDHI methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.
AB - We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RARβ, 11% for GSTP1, 7% for p16INK4A, 4% for DAPK, and 2% for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDHI methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=0035893756&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035893756&partnerID=8YFLogxK
M3 - Article
C2 - 11751381
AN - SCOPUS:0035893756
SN - 0008-5472
VL - 61
SP - 8659
EP - 8663
JO - Cancer research
JF - Cancer research
IS - 24
ER -